Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 1.00 |
| ▸ | CA2 | P00918 | 12/20 | 1.00 |
| ▸ | CA9 | Q16790 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | CA5A | P35218 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.65 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.65 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540915 | 0.92 | CA1 (0.85) | CA1CA2CA9HTTCA12 | |
| SCHEMBL11793140 | 0.92 | CA1 (0.85) | CA1CA2CA9HTTCA12 | |
| SCHEMBL19603195 | 0.86 | CA1 (0.76) | CA1CA2CA9HTTCA12 | |
| SCHEMBL27466837 | 0.85 | CA1 (1.00) | CA1CA2CA9HTTCA12 | |
| SCHEMBL11683906 | 0.83 | CA1 (0.71) | CA1CA2CA9HTTCA12 | |
| SCHEMBL2240008 | 0.83 | CA1 (0.71) | CA1CA2CA9HTTCA12 | |
| SCHEMBL1417537 | 0.83 | CA1 (0.71) | CA1CA2CA9HTTCA12 | |
| SCHEMBL7565259 | 0.83 | CA1 (0.73) | CA1CA2CA9HTTCA12 | |
| SCHEMBL4573594 | 0.83 | CA1 (0.74) | CA1CA2CA9HTTKMT2A | |
| SCHEMBL3086764 | 0.83 | CA1 (0.74) | CA1CA2CA9HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449247-B2 | Compositions and methods for enhancing immune response | AVIVAGEN INC. (CA) | 2019-10-22 | — | — | US | claimed |
| EP-2953624-B1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LUODA PHARMA LTD (IE) | 2019-08-21 | — | — | EP | claimed |
| US-9402697-B2 | Modification of ceramic surfaces | RESEARCH TRIANGLE INSTITUTE (US) | 2016-08-02 | — | — | US | claimed |
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Limited (IE) | 2016-01-07 | — | — | US | claimed |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Limited (IE) | 2015-12-24 | — | — | US | claimed |
| EP-2953623-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| EP-2953624-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | Luoda Pharma Pty Ltd (AU) | 2015-12-16 | — | — | EP | claimed |
| US-8993117-B2 | Devices with multiple surface functionality | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-03-31 | — | — | US | claimed |
| US-20150064654-A1 | MODIFICATION OF CERAMIC SURFACES | RES TRIANGLE INST (US) | 2015-03-05 | — | — | US | claimed |
| WO-2014121342-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | LUODA PHARMA PTY LIMITED (AU) | 2014-08-14 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0981273-A1 | ADHESIVE, ANTIMICROBIAL AND/OR REPARATIVE DENTIN STIMULATING DENTAL COMPOSITIONS AND METHODS FOR FORMING AND USING SUCH COMPOSITIONS | Ultradent Products, Inc. (US) | 2000-03-01 | — | — | EP | claimed |
| WO-1998036639-A1 | ADHESIVE, ANTIMICROBIAL AND/OR REPARATIVE DENTIN STIMULATING DENTAL COMPOSITIONS AND METHODS FOR FORMING AND USING SUCH COMPOSITIONS | ULTRADENT PRODUCTS, INC. (US) | 1998-08-27 | — | — | WO | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
| WO-1992014456-A1 | USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1992-09-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000748-A1 | METHODS OF TREATING TOPICAL MICROBIAL INFECTIONS | TSLP, CCL11, IL17A | CA1 2912/4885CA2 204/4885CA9 792/4885 |
| US-20150366797-A1 | METHODS OF TREATING MICROBIAL INFECTIONS, INCLUDING MASTITIS | LCT, TSLP, MLEC | CA1 1919/4885CA2 311/4885CA9 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.